Nothing Special   »   [go: up one dir, main page]

BR112016003201A2 - inibidores de grp94 seletivos e usos dos mesmos - Google Patents

inibidores de grp94 seletivos e usos dos mesmos

Info

Publication number
BR112016003201A2
BR112016003201A2 BR112016003201A BR112016003201A BR112016003201A2 BR 112016003201 A2 BR112016003201 A2 BR 112016003201A2 BR 112016003201 A BR112016003201 A BR 112016003201A BR 112016003201 A BR112016003201 A BR 112016003201A BR 112016003201 A2 BR112016003201 A2 BR 112016003201A2
Authority
BR
Brazil
Prior art keywords
grp94 inhibitors
selective grp94
compounds
effective amount
selective
Prior art date
Application number
BR112016003201A
Other languages
English (en)
Inventor
Yang Chenghua
Chiosis Gabriela
J Patel Hardik
Patel Pallav
Yan Pengrong
O Ochiana Stefan
Taldone Tony
Sun Weilin
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112016003201A2 publication Critical patent/BR112016003201A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Library & Information Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)

Abstract

a presente invenção refere-se a novos inibidores de grp94 seletivos, composições compreendendo uma quantidade eficaz de tais compostos e métodos para tratar ou prevenir uma condição, tal como câncer, compreendendo administração a um animal com necessidade do mesmo de uma quantidade eficaz de tais compostos.
BR112016003201A 2013-08-16 2014-08-15 inibidores de grp94 seletivos e usos dos mesmos BR112016003201A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361866932P 2013-08-16 2013-08-16
PCT/US2014/051332 WO2015023976A2 (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112016003201A2 true BR112016003201A2 (pt) 2017-11-21

Family

ID=52468819

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003201A BR112016003201A2 (pt) 2013-08-16 2014-08-15 inibidores de grp94 seletivos e usos dos mesmos

Country Status (17)

Country Link
US (3) US10421758B2 (pt)
EP (1) EP3033338A4 (pt)
JP (2) JP6539275B2 (pt)
KR (1) KR102319582B1 (pt)
CN (1) CN105899503B (pt)
AU (2) AU2014306417C1 (pt)
BR (1) BR112016003201A2 (pt)
CA (1) CA2921571C (pt)
EA (1) EA201690406A1 (pt)
HK (1) HK1226063A1 (pt)
IL (2) IL244251B (pt)
MX (1) MX370664B (pt)
PH (1) PH12016500511A1 (pt)
SG (2) SG11201601542SA (pt)
TW (1) TWI711618B (pt)
WO (1) WO2015023976A2 (pt)
ZA (1) ZA201601794B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
MX340714B (es) 2009-10-07 2016-07-22 Sloan-Kettering Inst For Cancer Res * Inhibidores de hsp90.
AU2012240079B2 (en) 2011-04-05 2017-05-18 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EP3030682B1 (en) * 2013-08-05 2020-06-03 Twist Bioscience Corporation De novo synthesized gene libraries
CN105899503B (zh) 2013-08-16 2020-08-18 纪念斯隆-凯特琳癌症中心 选择性grp94抑制剂和其用途
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
EA201790444A1 (ru) * 2014-09-17 2017-08-31 Мемориал Слоун Кеттеринг Кэнсэ Сентр Hsp90-направленная визуализация и терапия воспаления и инфекции
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
CN108503643B (zh) * 2017-02-28 2020-09-15 泉州易初生物医药科技有限公司 蛋白酶抑制剂的制备方法
EP3595636A4 (en) * 2017-03-16 2021-01-13 Children's Medical Center Corporation ENGINEERED LIPOSOMES USED AS THERAPEUTIC AGENTS TARGETING CANCER
EP3737683A4 (en) * 2018-01-02 2022-01-05 Sanford Burnham Prebys Medical Discovery Institute LOW MOLECULAR WEIGHT (LMPTP) INHIBITORS OF PROTEINTYROSIN PHOSPHATASE AND USES THEREOF
WO2021020845A1 (en) * 2019-07-26 2021-02-04 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
KR102728754B1 (ko) 2020-06-09 2024-11-13 국민대학교산학협력단 Grp94에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 및 이들의 용도
EP4163298A4 (en) * 2020-06-09 2024-06-12 Kookmin University Industry Academy Cooperation Foundation ANTIBODY SPECIFICALLY BINDING GRP94 OR AN ANTIGEN-BINDING FRAGMENT THEREOF, AND USES THEREOF
KR102751799B1 (ko) 2020-06-09 2025-01-13 주식회사 하울바이오 Grp94에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 및 이를 포함하는 약제학적 조성물
KR20230000050A (ko) 2021-06-24 2023-01-02 최현지 페이크 마스크
CN113663078B (zh) * 2021-06-28 2023-05-16 四川大学 Grp94抑制剂在制备治疗EGFR驱动的癌症的药物中的用途
KR20240012846A (ko) 2022-07-21 2024-01-30 성균관대학교산학협력단 신규한 hdac6 선택적 억제제 및 이의 용도
CN115717144A (zh) * 2022-08-25 2023-02-28 南通市肿瘤医院 抑制hsp90b1表达的小干扰rna及其在膀胱癌衰老中的应用
WO2024059745A2 (en) * 2022-09-15 2024-03-21 Bexson Biomedical, Inc. N-methyl-d-aspartate receptor (nmdar) antagonists and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425661T2 (de) * 1993-07-15 2001-04-19 Minnesota Mining And Mfg. Co., St. Paul IMIDAZO [4,5-c]PYRIDIN-4-AMINE
AU2002228771B2 (en) * 2000-11-02 2007-10-25 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to HSP90
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
MXPA06002997A (es) 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
CA2634723A1 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
JP2009536960A (ja) * 2006-05-12 2009-10-22 ミリアド ジェネティクス， インコーポレイテッド 治療用化合物および癌におけるそれらの使用
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
AU2007305166A1 (en) 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
ES2430217T3 (es) * 2007-03-20 2013-11-19 Curis, Inc. Aminopiridina condensada como inhibidores de HSP90
CN101909440A (zh) 2007-11-14 2010-12-08 瑞科西有限公司 治疗用化合物及其在治疗疾病和障碍中的用途
WO2010042500A2 (en) * 2008-10-06 2010-04-15 Emory University Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
MX340714B (es) 2009-10-07 2016-07-22 Sloan-Kettering Inst For Cancer Res * Inhibidores de hsp90.
AU2012240079B2 (en) 2011-04-05 2017-05-18 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
WO2012139010A1 (en) 2011-04-08 2012-10-11 University Of Kansas Grp94 inhibitors
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
AU2012282903A1 (en) * 2011-07-08 2014-02-13 Sloan-Kettering Institute For Cancer Research Uses of labeled HSP90 inhibitors
CN105899503B (zh) * 2013-08-16 2020-08-18 纪念斯隆-凯特琳癌症中心 选择性grp94抑制剂和其用途

Also Published As

Publication number Publication date
EA201690406A1 (ru) 2016-08-31
US20200102312A1 (en) 2020-04-02
US20160194328A1 (en) 2016-07-07
SG10201801281QA (en) 2018-04-27
WO2015023976A2 (en) 2015-02-19
CN105899503A (zh) 2016-08-24
JP2016533384A (ja) 2016-10-27
JP2019178147A (ja) 2019-10-17
IL267681A (en) 2019-08-29
PH12016500511A1 (en) 2016-06-13
IL244251B (en) 2019-07-31
US10421758B2 (en) 2019-09-24
IL267681B (en) 2022-11-01
TW201516047A (zh) 2015-05-01
IL267681B2 (en) 2023-03-01
AU2019202669A1 (en) 2019-05-09
AU2014306417B2 (en) 2019-01-17
TWI711618B (zh) 2020-12-01
CN105899503B (zh) 2020-08-18
WO2015023976A3 (en) 2015-04-23
HK1226063A1 (zh) 2017-09-22
EP3033338A4 (en) 2017-06-14
SG11201601542SA (en) 2016-04-28
EP3033338A2 (en) 2016-06-22
MX2016002077A (es) 2016-07-21
MX370664B (es) 2019-12-19
JP6848009B2 (ja) 2021-03-24
IL244251A0 (en) 2016-04-21
US11267816B2 (en) 2022-03-08
AU2019202669B2 (en) 2020-12-03
AU2014306417A1 (en) 2016-03-17
AU2014306417C1 (en) 2019-07-25
ZA201601794B (en) 2019-09-25
JP6539275B2 (ja) 2019-07-03
CA2921571A1 (en) 2015-02-19
US20230123747A1 (en) 2023-04-20
KR102319582B1 (ko) 2021-11-04
CA2921571C (en) 2022-04-05
KR20160043534A (ko) 2016-04-21

Similar Documents

Publication Publication Date Title
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
DOP2016000253A (es) Nuevos compuestos
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015032763A2 (pt) cd33 solúvel para tratar síndromes mielodisplásicas (mds)
BR112017018198A2 (pt) inibição da atividade de olig2
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
ZA201901367B (en) Inhibition of olig2 activity
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.